1.Hansrivijit P, RP Gale, J Barrett, and SO Ciurea. Cellular therapy for acute myeloid Leukemia - Current status and future prospects. Blood Rev. 2019;
2.Liu Y, Z Cheng, Y Pang, L Cui, T Qian, L Quan, H Zhao, J Shi, X Ke, and L Fu. Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia. J Hematol Oncol. 2019;12(1):51.
3.Zhou JD, XX Li, TJ Zhang, ZJ Xu, ZH Zhang, Y Gu, XM Wen, W Zhang, RB Ji, ZQ Deng, J Lin, and J Qian. MicroRNA–335/ID4 dysregulation predicts clinical outcome and facilitates leukemogenesis by activating PI3K/Akt signaling pathway in acute myeloid leukemia. Aging (Albany NY). 2019;
4.Liu L, J Ma, L Qin, X Shi, H Si, and Y Wei. Interleukin–24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell. Medicine (Baltimore). 2019;98(22):e15875.
5.Manola KN, F Panitsas, S Polychronopoulou, A Daraki, M Karakosta, C Stavropoulou, G Avgerinou, E Hatzipantelis, G Pantelias, C Sambani, and M Pagoni. Cytogenetic abnormalities and monosomal karyotypes in children and adolescents with acute myeloid leukemia: correlations with clinical characteristics and outcome. Cancer Genet. 2013;206(3):63–72.
6.Bret C, E Viziteu, A Kassambara, and J Moreaux. Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy. Expert Rev Hematol. 2016;9(4):351–60.
7.Wang BH, YH Li, and L Yu. Genomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid Leukemia. Chin Med J (Engl). 2015;128(17):2395–403.
8.Cai SF and RL Levine. Genetic and epigenetic determinants of AML pathogenesis. Semin Hematol. 2019;56(2):84–89.
9.Yu G, F Li, Y Qin, X Bo, Y Wu, and S Wang. GOSemSim: an R package for measuring semantic similarity among GO terms and gene products. Bioinformatics. 2010;26(7):976–978.
10.Ritchie ME, B Phipson, D Wu, Y Hu, CW Law, W Shi, and GK Smyth. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
11.Yu G, LG Wang, Y Han, and QY He. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7.
12.Subramanian A, P Tamayo, VK Mootha, S Mukherjee, BL Ebert, MA Gillette, A Paulovich, SL Pomeroy, TR Golub, ES Lander, and JP Mesirov. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.
13.Langfelder P and S Horvath. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9(559.
14.Szklarczyk D, A Franceschini, S Wyder, K Forslund, D Heller, J Huerta-Cepas, M Simonovic, A Roth, A Santos, KP Tsafou, M Kuhn, P Bork, LJ Jensen, and C von Mering. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(Database issue):D447–52.
15.Langfelder P, B Zhang, and S Horvath. Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R. Bioinformatics. 2008;24(5):719–20.
16.Voineagu I, X Wang, P Johnston, JK Lowe, Y Tian, S Horvath, J Mill, RM Cantor, BJ Blencowe, and DH Geschwind. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature. 2011;474(7351):380–4.
17.Ravasz E, AL Somera, DA Mongru, ZN Oltvai, and AL Barabasi. Hierarchical organization of modularity in metabolic networks. Science. 2002;297(5586):1551–5.
18.Shannon P, A Markiel, O Ozier, NS Baliga, JT Wang, D Ramage, N Amin, B Schwikowski, and T Ideker. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.
19.Colaprico A, TC Silva, C Olsen, L Garofano, C Cava, D Garolini, TS Sabedot, TM Malta, SM Pagnotta, I Castiglioni, M Ceccarelli, G Bontempi, and H Noushmehr. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71.
20.Livak KJ and TD Schmittgen. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8.
21.Tan H, K Yang, Y Li, TI Shaw, Y Wang, DB Blanco, X Wang, JH Cho, H Wang, S Rankin, C Guy, J Peng, and H Chi. Integrative Proteomics and Phosphoproteomics Profiling Reveals Dynamic Signaling Networks and Bioenergetics Pathways Underlying T Cell Activation. Immunity. 2017;46(3):488–503.
22.Jansen R, D Greenbaum, and M Gerstein. Relating whole-genome expression data with protein-protein interactions. Genome Res. 2002;12(1):37–46.
23.Avellino R and R Delwel. Expression and regulation of C/EBPalpha in normal myelopoiesis and in malignant transformation. Blood. 2017;129(15):2083–2091.
24.Paietta E. Expression of cell-surface antigens in acute promyelocytic leukaemia. Best Practice & Research Clinical Haematology. 2003;16(3):17.
25.JT R. Class III receptor tyrosine kinases: role in leukaemogenesis. Br J Haematol. 2002;116(4):14.
26.Fassunke J, MC Blum, HU Schildhaus, M Zapatka, B Brors, H Kunstlinger, R Buttner, E Wardelmann, and S Merkelbach-Bruse. qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL. BMC Mol Biol. 2010;11(100.
27.Kacinski BM. CSF–1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Mol Reprod Dev. 1997;46(1):71–4.
28.Liang DC, LY Shih, IJ Hung, CP Yang, SH Chen, TH Jaing, HC Liu, and WH Chang. Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia. Cancer. 2002;94(12):3292–8.
29.Boissel N, H Leroy, B Brethon, N Philippe, S de Botton, A Auvrignon, E Raffoux, T Leblanc, X Thomas, O Hermine, B Quesnel, A Baruchel, G Leverger, H Dombret, C Preudhomme, A Acute Leukemia French, and G Leucemies Aigues Myeloblastiques de l’Enfant Cooperative. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20(6):965–70.
30.Stam RW, I Hubeek, ML den Boer, JG Buijs-Gladdines, U Creutzig, GJ Kaspers, and R Pieters. MLL gene rearrangements have no direct impact on Ara-C sensitivity in infant acute lymphoblastic leukemia and childhood M4/M5 acute myeloid leukemia. Leukemia. 2006;20(1):179–82.
31.Vaughn JE, V Shankaran, and RB Walter. Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come? Curr Hematol Malig Rep. 2019;
32.Pollyea DA. New drugs for acute myeloid leukemia inspired by genomics and when to use them. Hematology Am Soc Hematol Educ Program. 2018;2018(1):45–50.
33.Bullinger L, K Dohner, and H Dohner. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. J Clin Oncol. 2017;35(9):934–946.
34.Papaemmanuil E, H Dohner, and PJ Campbell. Genomic Classification in Acute Myeloid Leukemia. N Engl J Med. 2016;375(9):900–1.
35.Blume-Jensen P and T Hunter. Oncogenic kinase signalling. Nature. 2001;411(6835):355–65.
36.Shlush LI, S Zandi, A Mitchell, WC Chen, JM Brandwein, V Gupta, JA Kennedy, AD Schimmer, AC Schuh, KW Yee, JL McLeod, M Doedens, JJ Medeiros, R Marke, HJ Kim, K Lee, JD McPherson, TJ Hudson, HP-LGP Consortium, AM Brown, F Yousif, QM Trinh, LD Stein, MD Minden, JC Wang, and JE Dick. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506(7488):328–33.
37.Sun YX, HL Kong, CF Liu, S Yu, T Tian, DX Ma, and CY Ji. The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia. Hum Immunol. 2014;75(2):113–8.
38.Tian T, S Yu, L Liu, F Xue, C Yuan, M Wang, C Ji, and D Ma. The Profile of T Helper Subsets in Bone Marrow Microenvironment Is Distinct for Different Stages of Acute Myeloid Leukemia Patients and Chemotherapy Partly Ameliorates These Variations. PLoS One. 2015;10(7):e0131761.
39.Moschovakis GL and R Forster. Multifaceted activities of CCR7 regulate T-cell homeostasis in health and disease. Eur J Immunol. 2012;42(8):1949–55.
40.Xu B, K Aoyama, M Kusumoto, A Matsuzawa, EC Butcher, SA Michie, T Matsuyama, and T Takeuchi. Lack of lymphoid chemokines CCL19 and CCL21 enhances allergic airway inflammation in mice. Int Immunol. 2007;19(6):775–84.
41.Bettelli E, M Oukka, and VK Kuchroo. T(H)–17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8(4):345–50.
42.Tesmer LA, SK Lundy, S Sarkar, and DA Fox. Th17 cells in human disease. Immunol Rev. 2008;223(87–113.
43.Cua DJ, J Sherlock, Y Chen, CA Murphy, B Joyce, B Seymour, L Lucian, W To, S Kwan, T Churakova, S Zurawski, M Wiekowski, SA Lira, D Gorman, RA Kastelein, and JD Sedgwick. Interleukin–23 rather than interleukin–12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003;421(6924):744–8.
44.Le Dieu R, DC Taussig, AG Ramsay, R Mitter, F Miraki-Moud, R Fatah, AM Lee, TA Lister, and JG Gribben. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood. 2009;114(18):3909–16.
45.AD L. The role of chemokines in linking innate and adaptive immunity. CURR OPIN IMMUNOL. 2002;14(1):7.
46.Noelia Sánchez-Sánchez LR-B, Gonzalo de la Rosa, Amaya Puig-Kröger, Julio García-Bordas, Daniel Martín, Natividad Longo, Antonio Cuadrado, Carlos Cabañas, Angel L. Corbí, Paloma Sánchez-Mateos and José Luis Rodríguez-Fernández. Chemokine receptor CCR7 induce intracellular signaling that inhibits apoptosis of mature dendritic cells. blood. 2004;104(
47.Bauvois B. New facets of matrix metalloproteinases MMP–2 and MMP–9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta. 2012;1825(1):29–36.
48.Foroushani A, R Agrahari, R Docking, L Chang, G Duns, M Hudoba, A Karsan, and H Zare. Large-scale gene network analysis reveals the significance of extracellular matrix pathway and homeobox genes in acute myeloid leukemia: an introduction to the Pigengene package and its applications. BMC Med Genomics. 2017;10(1):16.
49.Lane WJ, S Dias, K Hattori, B Heissig, M Choy, SY Rabbany, J Wood, MA Moore, and S Rafii. Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood. 2000;96(13):4152–9.
50.Janowska-Wieczorek A, LA Marquez, A Dobrowsky, MZ Ratajczak, and ML Cabuhat. Differential MMP and TIMP production by human marrow and peripheral blood CD34(+) cells in response to chemokines. Exp Hematol. 2000;28(11):1274–85.
51.Kittang AO, K Hatfield, K Sand, H Reikvam, and O Bruserud. The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications. Curr Top Microbiol Immunol. 2010;341(149–72.
52.McQuibban GA, GS Butler, JH Gong, L Bendall, C Power, I Clark-Lewis, and CM Overall. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor–1. J Biol Chem. 2001;276(47):43503–8.
53.Lee KM, K Nam, S Oh, J Lim, YP Kim, JW Lee, JH Yu, SH Ahn, SB Kim, DY Noh, T Lee, and I Shin. Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling. Breast Cancer Res. 2014;16(6):479.
54.Hatfield KJ, H Reikvam, and O Bruserud. The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia. Curr Med Chem. 2010;17(36):4448–61.
55.Van den Steen PE, P Proost, A Wuyts, J Van Damme, and G Opdenakker. Neutrophil gelatinase B potentiates interleukin–8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF–4, and GRO-alpha and leaves RANTES and MCP–2 intact. Blood. 2000;96(8):2673–81.
56.Reikvam H, KJ Hatfield, AM Oyan, KH Kalland, AO Kittang, and O Bruserud. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. Eur J Haematol. 2010;84(3):239–51.
57.Hatfield KJ, AM Olsnes, BT Gjertsen, and O Bruserud. Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr Cancer Drug Targets. 2005;5(4):229–48.
58.Leifler KS, S Svensson, A Abrahamsson, C Bendrik, J Robertson, J Gauldie, AK Olsson, and C Dabrosin. Inflammation induced by MMP–9 enhances tumor regression of experimental breast cancer. J Immunol. 2013;190(8):4420–30.